






JOB OFFER							
REFERENCE		OPENING DATE		DEADLINE			
APG/21		03/12/2024		12/12/2024			
PROFILE REQUIREMENTS							
EXCLUSIVE REQUIREMENTS: (1)							
• Baccalaureate / intermediate technical qualification in the field of health care (justification must be provided with the application).							
VALUED MERITS /SKYLLS							
FURTHER	Good clinical practice training certificate						
EXPERIENCE		More tan 15 years as a technician in the coordination of clinical trials in all phases of clinical oncology					
OTHERS		Experience in managing IVRS /IWRS medication randomization and refill systems					
CONTRACT INFORMATION							
TYPE OF CONTRACT		EXPECTED INCORPORATION DATE		JOB STATUS			
Contract for scientific-technical activities (article 23.bis of Law 14/2011, of June 1, on Science, Technology and Innovation)		16/12/2024		Full time. 1800hours per year (aprox. 40 h/week)			
ANNUAL GROSS SA	LARY	DURATION OF THE CONTRACT					
18.144,00 € without prejudice to the basic update established in state legislation for 2024.		Indefinite (linked to the duration of the project or to external financing or financing from public grants in full competition).					
WORK LOCATION	UNIT/DEPARTMENT						
Building, Valdecilla Sur, 2nd floor, oncology consultations		Oncology Service					
		JOB DETAILS	5				
	OF	FER DESCRIPTI	ON				
	Resea	rch support tech	nnician				
		FUNCTIONS					
 Management of interactive radiology platforms. Sending and processing of biological samples Management of study test Monitoring visit. Attention to the study monitor 							
PRINCIPAL INVESTIGATOR RESPONSABLE	/ RESEAR	RCH GROUP	RESEARCH PROJECT				
Fernando Rivera Herrero	Oncology S	ervice	2023.312 A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal				

RECRUITMENT INFORMATION

Av. Cardenal Herrera Oria s/n 39011 Santander - España www.idival.org Tel. +34 942 31 55 15 Fundación Instituto de Investigación Marqués de Valdecilla CIF: G 39788773

EMPLOYMENT EXCHANGE

Adenocarcinoma.



SELECTION PROCESS STAGES (2)

DIRECCIÓN DE VALIDACIÓN : https://portafirmas.redsara.es/pf/valida

FIRMANTE(1): FRANCISCO GALO PERALTA FERNANDEZ | FECHA: 03/12/2024 10:24 | Sin acción específica









- 1. Admission of applications.
- 2. Competition phase.
- 3. Interview pase: maximum number of candidates to be interviewed: 4
- 4. Report of the Tribunal.
- 5. Resolution.

NOT

<u>Note:</u> in order for candidates to be considered for recruitment and employment exchange purposes, they must have a total score of at least 30 points.

SELECTION BOARD

- President: Fernando Rivera Herrero, Investigador Principal.
- Member: Francisco Galo Peralta, IDIVAL Management Director.
- Member and secretary: be Maria José Marín Vidalled, Coordinator of IDIVAL's Technological Services.

VALUATION OF MERITS								
MERITS	EVALUATION	SCOR	MAXIMUM					
Good clinical practice training certificate	CV	Merit fullfilment	YES/NO	8				
More tan 15 years as a technician in the coordination of clinical trials in all phases of clinical oncology	CV	Merit fullfilment	YES/NO	30				
Experience in managing IVRS /IWRS medication randomization and refill systems	CV	Merit fullfilment	YES/NO	22				
FINAL SCORE								
MAXIMUM TOTAL SCORE BY MERITS								
MAXIMUM TOTAL SCORE IN INTERVIEW								
MAXIMUM TOTAL SCORE								

- (1) Not subsanable
- (2) See duration of each phase in the document "Selection Process"

In compliance with the provisions of Article 11 of Organic Law 3/2018, you are informed that the person responsible for the processing of your personal data is the MARQUES DE VALDECILLA INSTITUTE OF INVESTIGATION FOUNDATION (IDIVAL), your data will be treated in order to be treated to the extent that they were necessary or convenient for the development of the legal relationship established between the parties. You can exercise your rights of access, rectification, deletion, opposition, portability or limitation of the treatment, by contacting the IDIVAL FOUNDATION at the following address: AVDA. CARDENAL HERRERA ORIA, S / N 39007, SANTANDER. More information at www.idival.org/es/Politica-de-Privacidad

Santander as of the date of electronic signature

Fdo. Francisco Galo Peralta Fernandez



www.idival.org Tel. +34 942 31 55 15 Fundación Instituto de Investigación Marqués de Valdecilla CIF: G 39788773

